Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai HeartCare Medical Technology Corporation Limited
上海心瑋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6609)

RETIREMENT OF NON-EXECUTIVE DIRECTOR; PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR; POSTPONEMENT OF EGM; AND REVISED DATE OF CLOSURE OF H SHARE REGISTER OF MEMBERS

RETIREMENT OF NON-EXECUTIVE DIRECTOR

Reference is made to the Company's announcement dated October 26, 2026, the circular (the "**Original Circular**") and notice of the 2026 third extraordinary general meeting (the "**Original EGM Notice**") each dated October 29, 2026 and the form of proxy (the "**Original Proxy Form**") regarding the proposed re-election and appointment of the board (the "**Board**") of directors (the "**Director(s)**") of Shanghai HeartCare Medical Technology Corporation Limited (the "**Company**"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as used in the Original Circular.

Subsequent to the publication of the Original Circular, Mr. CHEN Gang ("**Mr. Chen**") has notified the Company that he intends to retire from his role as a non-executive Director of the Company and does not seek to be re-elected as a non-executive Director due to his other work arrangements at the upcoming EGM upon which a new session of the Board is due to be elected (which has currently been postponed to November 26, 2026). Mr. Chen will also cease to be a member of the strategy committee of the Board upon his retirement as a non-executive Director.

Mr. Chen has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of Hong Kong Stock Exchange and the Shareholders.

The Board would like to take this opportunity to express its gratitude to Mr. Chen for his contributions to the Company during his tenure of office as a non-executive director of the Company.

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

The Board further announces that upon receiving Mr. Chen's notification to retire from the Board, on November 9, 2026, the Board proposed to appoint Mr. ZHANG Han ("**Mr. Zhang**"), the Company's senior vice president, chief operating officer, chief financial officer, board secretary and a joint company secretary, as an executive Director and as a member of the strategy committee of the Board. The proposed appointment as an executive Director is subject to the approval by the Shareholders at the 2026 third extraordinary general meeting of the Company (the "**EGM**") to be held on November 26, 2026 in accordance with the articles of association of the Company. The term of office for Mr. Zhang shall be three years commencing from the date of approval at the EGM.

Subsequently, the Third Session of the Board will consist of nine Directors, including four executive Directors, two non-executive Directors and three independent non-executive Directors.

Biographical details of Mr. Zhang

Mr. Zhang, aged 39, as the senior vice president, chief operating officer, chief financial officer, board secretary and a joint company secretary of our Company, mainly responsible for taking the lead in the Company's strategic execution work, assisting the Chairman in coordinating the daily operation and management of the enterprise, as well as the Company's financial compliance, investment and financing, and market value management. Mr. Zhang joined our Company in November 2020 and appointed as the senior vice president, chief financial officer and board secretary on November 23, 2020. He was appointed as our company secretary on December 22, 2020 and was further appointed as our chief operating officer in March 2025. Mr. Zhang serves as a supervisor of two wholly-owned subsidiaries of our Company, namely Nanjing Sealmedical Technology Co., Ltd. (南京思脈德醫療科技有限公司) and Weiming (Shanghai) Medical Device Co., Ltd. (瑋銘醫療器械(上海)有限公司), and he also holds various directorship roles with subsidiaries of the Group.

Mr. Zhang has extensive experience in equity capital market and financial management. Mr. Zhang started to work at Ernst & Young Hua Ming LLP (安永華明會計師事務所(特殊普通合夥)) in December 2009 and left as a senior associate in June 2012. From June 2012 to November 2020, he served as a senior manager, a director and an executive director of investment banking at Sinolink Securities Corporation Limited (國金證券股份有限公司), where he was responsible for the corporate finance and M&A business in healthcare sector.

Mr. Zhang obtained his bachelor's degree in accounting and international economic law from Shanghai University of Finance and Economics (上海財經大學) in the PRC in July 2009, and a master of business administration from China Europe International Business School (中歐國際工商學院) in November 2024. He is a member of CICPA since March 2014 and also a member of Certified Public Accountants Association of Australia since June 2012.

Mr. Zhang holds 1,000,000 Unlisted Shares of the Company, representing approximately 12.09% of the outstanding issued Unlisted Shares of the Company, he also holds 72,000 H Shares of the Company and is interested in 168,000 unvested H Shares granted to him under the Company's 2025 H Share Incentive Scheme, which in aggregate represents 0.79% of the outstanding H Shares of the Company (excluding any treasury Shares), and 3.19% of the total issued Shares of the Company (excluding any treasury Shares).

Save as disclosed in this announcement, as at the date of this announcement, Mr. Zhang: (i) did not have any other relationship with any other director, senior management or substantial or controlling shareholders of the Company (within the definition of the Listing Rules); (ii) did not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance; (iii) did not hold any other position with any member of the Group; (iv) had not held any directorship in any other companies listed in Hong Kong or overseas in the last three years; (v) had no other major appointment or professional qualification; and (vi) had no information that is required to be disclosed pursuant to Rules 13.51(2) of the Listing Rules nor any other matter that needs to be brought to the attention of the shareholders of the Company.

POSTPONEMENT OF THE EGM

As Mr. Chen no longer seeks to be re-elected to the third session of the Board, ordinary resolution number 4 set out in the Original EGM Notice and the Original Proxy Form in relation to his proposed appointment as a non-executive Director will be withdrawn and will instead be replaced by an ordinary resolution to appoint Mr. Zhang as an executive Director to the third session of the Board.

Due to the additional resolution to be submitted to the Shareholders for consideration and the additional time required by the Company to prepare the relevant materials, the Company hereby announces the postponement of the EGM (the "**Postponed EGM**") to November 26, 2026.

A supplemental circular (the "**Supplemental Circular**"), containing among other things, further information regarding the election of Mr. Zhang as an executive Director, together with a supplemental notice of the Postponed EGM (the "**Supplemental EGM Notice**") and a supplemental proxy form (the "**Revised Proxy Form**") will be published on the websites of the Stock Exchange and the Company on or before November 11, 2026.

Special arrangements for the completion and return of the Revised Proxy Form will also be set out in the Supplemental EGM Notice. Shareholders who have appointed or intend to appoint any proxy to attend the Postponed EGM are requested to pay particular attention to the special arrangements to be set out therein.

REVISED DATE OF CLOSURE OF H SHARE REGISTER OF MEMBERS

As set out in the Original Circular, the register of members of the Company is originally scheduled to be closed from Tuesday, November 10, 2026 to Friday, November 13, 2026, both days inclusive, during which period no transfer of shares of the Company will be registered, in order to determine the identity of the Shareholders who are entitled to attend and vote at the EGM.

Due to the postponement of the EGM, the period during which the register of members will be closed in order to determine the identity of the Shareholders who are entitled to attend and vote at the Postponed EGM (during which period no share transfers will be registered) will also be changed. The revised book closure period will be from Monday, November 23, 2026 to Thursday, November 26, 2026, both days inclusive, during which period no transfer of shares will be effected. In order to be eligible to attend and vote at the Postponed EGM, all transfers of shares of the Company, accompanied by the relevant share certificates, must be lodged with the Company's branch share registrar and transfer office in Hong Kong. In order to be eligible for attending and voting at the EGM, all transfers documents of H Shares accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Friday, November 20, 2026 for registration.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, November 9, 2026

As at the date of this announcement, the Board comprises Mr. WANG Guohui, Ms. ZHANG Kun and Mr. WEI Jiawei as executive Directors; Mr. CHEN Shaoxiong and Mr. CHEN Gang as non-executive Directors; and Mr. GUO Shaomu, Mr. FENG Xiangqian and Mr. GONG Ping as independent non-executive Directors.